Shanghai Henlius Biotech (HKG:2696) has received a filing notice from the China Securities Regulatory Commission for its proposed H-share full circulation, according to a Friday Hong Kong bourse filing.
Shares of the biotech firm were down nearly 2% in Monday morning trade.
The filing covers the conversion and listing of 182.6 million domestic unlisted shares held by certain shareholders, the company said.
The CSRC filing marks the completion of the regulatory filing process for the full-circulation plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments